| Code | CSB-RA851547MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to reference antibody 23ME-00610, targeting CD200R1 (CD200 Receptor 1), an inhibitory immune checkpoint receptor predominantly expressed on myeloid cells including macrophages, dendritic cells, and certain T cell subsets. CD200R1 belongs to the immunoglobulin superfamily and delivers immunosuppressive signals upon binding its ligand CD200, playing a critical role in maintaining immune homeostasis and preventing excessive inflammatory responses. Dysregulation of the CD200-CD200R1 axis has been implicated in various pathological conditions, including autoimmune diseases, chronic inflammation, cancer immune evasion, and neurodegenerative disorders where aberrant immune suppression can promote disease progression.
This biosimilar antibody provides researchers with a reliable tool for investigating CD200R1-mediated immunoregulatory mechanisms and exploring therapeutic strategies targeting this checkpoint pathway. The antibody enables detailed characterization of CD200R1 expression patterns, functional studies of receptor-ligand interactions, and evaluation of immune modulation in disease models. It serves as a valuable reagent for immunology research, cancer biology studies, and therapeutic antibody development programs.
There are currently no reviews for this product.